7 research outputs found
Characteristics and serotype distribution of childhood cases of invasive pneumococcal disease following pneumococcal conjugate vaccination in England and Wales, 2006-14
Background The 7-valent (PCV7) and 13-valent (PCV13) pneumococcal conjugate vaccines are
highly effective in preventing invasive pneumococcal disease (IPD) caused by vaccine serotypes.
Vaccine failure (vaccine-type IPD after age-appropriate immunisation) is rare. Little is known about
the risk, clinical characteristics or outcomes of PCV13 compared to PCV7 vaccine failure.
Methods Public Health England conducts IPD surveillance and provides a national reference
service for serotyping pneumococcal isolates in England and Wales. We compared the
epidemiology, rates, risk factors, serotype distribution, clinical characteristics, and outcomes of IPD
in children with PCV13 and PCV7 vaccine failure.
Results A total of 163 episodes of PCV failure were confirmed in 161 children over eight years (04
September 2006 to 03 September 2014) in ten birth cohorts. After three vaccine doses, PCV7 and
PCV13 failure rates were 0.19/100,000 (95% CI, 0.10-0.33; 57 cases) and 0.66/100,000 (95% CI,
0.44-0.99; 104 cases) vaccinated person-years, respectively. Children with PCV13 failure were
more likely to be healthy (87/105 [82.9%] vs. 37/56 [66.1%]; P=0.02), present with bacteremic lower
respiratory tract infection (61/105 [58.1%] vs. 11/56 [19.6%]; P<0.001) and develop empyema
(41/61 [67.2%] vs. 1/11 [9.1%]; P<0.001) compared to PCV7 failures. Serotypes 3 (n=38, 36.2%)
and 19A (n=30, 28.6%) were responsible for most PCV13 failures. Five children died (3.1%; 95%
CI, 1.0-7.1%), including four with co-morbidities.
Conclusions PCV failure is rare and, compared to PCV7 serotypes, the additional PCV13
serotypes are more likely to cause bacteremic lower respiratory tract infection and empyema in
healthy vaccinated children
Invasive Haemophilus influenzae Infections after 3 Decades of Hib Protein Conjugate Vaccine Use.
Haemophilus influenzae serotype b (Hib) was previously the most common cause of bacterial meningitis and an important etiologic agent of pneumonia in children aged <5 years. Its major virulence factor is the polyribosyl ribitol phosphate (PRP) polysaccharide capsule. In the 1980s, PRP-protein conjugate Hib vaccines were developed and are now included in almost all national immunization programs, achieving a sustained decline in invasive Hib infections. However, invasive Hib disease has not yet been eliminated in countries with low vaccine coverage, and sporadic outbreaks of Hib infection still occur occasionally in countries with high vaccine coverage. Over the past 2 decades, other capsulated serotypes have been recognized increasingly as causing invasive infections. H. influenzae serotype a (Hia) is now a major cause of invasive infection in Indigenous communities of North America, prompting a possible requirement for an Hia conjugate vaccine. H. influenzae serotypes e and f are now more common than serotype b in Europe. Significant year-to-year increases in nontypeable H. influenzae invasive infections have occurred in many regions of the world. Invasive H. influenzae infections are now seen predominantly in patients at the extremes of life and those with underlying comorbidities. This review provides a comprehensive and critical overview of the current global epidemiology of invasive H. influenzae infections in different geographic regions of the world. It discusses those now at risk of invasive Hib disease, describes the emergence of other severe invasive H. influenzae infections, and emphasizes the importance of long-term, comprehensive, clinical and microbiologic surveillance to monitor a vaccine's impact